Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 30, 2011
ADVAXIS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
00028489
|
02-0563870
|
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
305 College Road East
Princeton, New Jersey 08540
(Address of principal executive offices)
Registrant’s telephone number, including area code: (609) 452-9813
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On June 30, 2011, Advaxis, Inc. (the “Company”) issued a press release announcing that it had been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on August 10, 2011 to discuss the CMC, pharmacology, toxicology, and clinical plans for Advaxis PSA, its construct to fight prostate cancer. A copy of the press release, which is attached as Exhibit 99.1 to this Current Report, is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
99.1 Advaxis, Inc. press release, dated June 30, 2011.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: June 30, 2011
|
Advaxis, Inc.
|
|
| |
|
|
|
| |
By:
|
/s/ Mark J. Rosenblum
|
|
| |
|
Mark J. Rosenblum
|
|
| |
|
Chief Financial Officer and Secretary
|
|
EXHIBIT INDEX
|
Exhibit No.
|
|
Document Description
|
| |
|
|
|
99.1
|
|
Advaxis, Inc. press release, dated June 30, 2011.
|